Kevin Moulder

Kevin has over 30 years’ experience in pharmaceutical discovery and development in the fields of oncology, inflammation, immunology, cardiovascular and infectious diseases. He has served in research leadership positions in 9 international biotechnology companies including Biogen, Domantis, F-Star and Tusk Therapeutics, where he served as Chief Development Officer until its acquisition in 2018 by Roche.

Kevin holds a BSc in biological sciences and a PhD in Immunology from the University of London.